Navigation Links
Anti-Clotting Drug May Cause Severe Bleeding With No Benefit
Date:7/25/2011

By Steven Reinberg
HealthDay Reporter

SUNDAY, July 24 (HealthDay News) -- For patients suffering chest pain, adding a new anti-clotting drug, Eliquis, to dual antiplatelet therapy may result in severe bleeding without reducing the risk of heart attack and stroke, a new study finds.

A trial evaluating the combination treatment was halted early when the risk of severe bleeding among those taking Eliquis (apixaban) became apparent.

"It is very clear there is an increased risk of bleeding, and in most patients it doesn't appear there is a lot of benefit to outweigh the risk of bleeding," said researcher Dr. John H. Alexander, co-director of cardiovascular research at the Duke Clinical Research Institute of Duke University Medical Center in Durham, N.C.

"We know high-risk patients with acute coronary syndromes continue to have events, and we know antiplatelet therapy is effective," said Alexander. The researchers expected to see some increase in bleeding when they added Eliquis to other anti-clotting therapy, but the bleeding was significant and "there was nothing to offset that increase in bleeding, so we stopped the trial," he said.

The conclusion: "Combination treatment with an anticoagulant and dual antiplatelet therapy should be avoided unless there is a clear indication for both, as in some patients with atrial fibrillation," Alexander said.

The report was published online July 24 in the New England Journal of Medicine to coincide with presentation of the study results at the International Society on Thrombosis and Haemostasis Congress, July 23-28 in Kyoto, Japan.

For the study, researchers randomly assigned 7,392 patients who were receiving standard antiplatelet therapy with two drugs to an additional 5 milligrams of Eliquis or a dummy pill twice daily. The study was double-blind, meaning that neither the patients nor the researchers knew who was taking Eliquis or a dummy pill.

Eliquis is a so-called Xa inhibitor, which is a class of anticoagulants that work by blocking factor X, a protein involved in blood clotting.

Over an average follow-up of eight months, 7.5 percent of the patients receiving Eliquis had a heart attack, suffered a stroke, or died, as did 7.9 percent of the patients receiving placebo, the researchers found.

In addition, 1.3 percent of those taking Eliquis had major bleeding, compared with 0.5 percent of those receiving the placebo, they noted.

Moreover, more patients taking Eliquis had bleeding into the brain and died from uncontrollable bleeding than patients receiving placebo, Alexander said.

Would a lower dose of Eliquis work? Alexander is skeptical. While it could reduce the risk of bleeding, he said he doubts more heart attacks, strokes or deaths would be prevented.

The trial was funded by Pfizer/Bristol-Myers Squibb, the makers of Eliquis.

Commenting on the study, Dr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles, said that "each year more than 1.4 million men and women are admitted to hospitals in the United States with acute coronary syndromes."

Despite conventional therapy, patients with acute coronary syndromes remain at risk for recurrent cardiovascular events, Fonarow said.

A number of medications that prevent blood clots (known as antithrombotic drugs) "are being evaluated in patients with acute coronary syndromes to determine if they can further reduce cardiovascular event risk without substantially increasing the bleeding risk when added to conventional therapies," he said.

Apixaban and two other drugs, rivaroxaban (Xarelto) and dabigatran (Pradaxa), have been shown to provide significant benefit in reducing stroke and clots in patients with atrial fibrillation, where the benefit outweighs the bleeding risk, Fonarow said.

"However, this new study suggests that the use of apixaban, at least at the dose studied, should be avoided in patients with recent acute coronary syndromes being treated with dual antiplatelet therapy," he said.

More information

For more information on heart disease, visit the U.S. Centers for Disease Control and Prevention.

SOURCES: John H. Alexander, M.D., co-director, Cardiovascular Research, Duke Clinical Research Institute, Duke University Medical Center, Durham, N.C.; Gregg C. Fonarow, M.D., professor, cardiology, University of California, Los Angeles; July 24, 2011, New England Journal of Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
2. Extended use of anti-clotting drug helps some bedridden patients
3. New Anti-Clotting Drug May Work Better After Hip Replacement
4. Anti-clotting agent does not improve outcomes of patients with severe pneumonia
5. Obstructive Sleep Apnea in Kids May Have Genetic Cause
6. UCLA study reveals how genes interact with their environment to cause disease
7. Virus Unlikely to Cause Chronic Fatigue Syndrome
8. RSA Innovator NetClarity Solves Networking Problems Caused by HP and Cisco Divorce
9. Popular nanoparticle causes toxicity in fish, study shows
10. Genetic cause discovered for rare bleeding disorder
11. Contact Dermatitis Can Be Irritating, Especially When the Cause is a Mystery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anti-Clotting Drug May Cause Severe Bleeding  With No Benefit
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Finally, a bruise ... venous procedures, dermaka cream can be incorporated into the post-surgical treatment plans of a ... procedures. , dermaka cream is very effective for bruising and causes a rapid ...
(Date:6/24/2016)... ... 24, 2016 , ... Southern Illinois University School of Dental ... Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy (MOM). They will host ... Collinsville. , They expect to treat approximately 2,000 patients from Illinois, ...
(Date:6/24/2016)... ... June 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona ... surrounded by famous vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new ... Lodge at Sedona as well as the Sedona Rouge, both popular accommodations for SpiritQuest ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) ... of ,world firsts,: , TwinLink™ - the ...
Breaking Medicine Technology: